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Ovarian cancer cells accumulate genetic
changes that allow them to evade
chemotherapeutic drugs and become
increasingly dangerous. In view of the
high mortality rates associated with ovar-
ian cancer, a better understanding of the
molecular mechanisms underlying tumor
progression in the disease could reveal
novel pathways of high clinical rele-
vance. A key feature of ovarian cancer is
its sensitivity to platinum salts such as
Cisplatin (CDDP) and Carboplatin, two
drugs that have been the mainstay of
therapy for decades. Unfortunately, ovar-
ian cancer cells, with their unstable
genomes, are initially sensitive to this
class of drugs, but the cells invariably
become resistant.
In a recent study, Taniguchi et al.
(2003) describe a model for ovarian
tumor progression in which the initial
methylation of FANCF, a gene associat-
ed with Fanconi anemia, is followed by
FANCF demethylation and CDDP resis-
tance. FANCF is one of seven recently
cloned Fanconi anemia genes whose
protein products were found to interact
with proteins involved in DNA repair
pathways, including BRCA1, RAD51,
ATM, and NBS1 (D’Andrea and Grompe,
2003). Five of the FANC gene products
(FANCA, FANCC, FANCE, FANCF, and
FANCG) are subunits of a nuclear com-
plex (FA complex) that is required for the
monoubiquitination of the downstream
FANCD2 protein (Figure 1A). The sev-
enth gene, FANCD1, was recently shown
to be identical to BRCA2 (Howlett et al.,
2002). Defects in the Fanconi-anemia-
BRCA (FA-BRCA) pathway are associat-
ed with genomic instability and
increased sensitivity to DNA-damaging
agents such as ionizing radiation (IR),
mitomycin C (MMC), and CDDP. In
response to ionizing radiation-mediated
double-strand breaks, ATM phosphory-
lates the NBS1 protein. Phosphorylation
of NBS1 is required for FANCD2 phos-
phorylation at serine 222, leading to acti-
vation of an S phase checkpoint. In
response to DNA damage, the FA com-
plex mediates ubiquitination of FANCD2
at lysine 561. Activated FANCD2 is
translocated to chromatin and DNA
repair foci, which contain the BRCA1
protein and BRCA2/FANCD1 protein
complex. BRCA2/FANCD1 binds to
RAD51 and to DNA, promoting a DNA
repair response. The ubiquinated
FANCD2 also colocalizes with NBS-
MRE11-RAD50 complex in DNA dam-
age nuclear foci. Germline mutation of
several genes in the pathway result in
impaired response to DNA damage and
increased cancer susceptibility.
FANCD2 exists as two isoforms in
normal cells, nonubiquitinated FANCD2-
S and monoubiquitinated FANCD2-L.
Inducible expression of monoubiquitinat-
ed FANCD2 in response to DNA damage
requires an intact FA-BRCA pathway.
Taniguchi et al.(2003) screened 25 ovar-
ian cancer cell lines with varying sensi-
tivities to CDDP and found two cell lines,
2008 and TOV-21G, without the
FANCD2-L isoform. Compared to other
ovarian cancer cell lines, both 2008 and
TOV-21G are hypersensitive to CDDP
with half maximal inhibitory concentra-
tion (IC50) less than 1.0 µm of CDDP.
TOV-21G cells were retrovirally trans-
duced with various FANC cDNAs
(FANCA, FANCC, FANCE, FANCF,
FANCG) in an attempt to correct any
FANCF methylation contributes to chemoselectivity in ovarian
cancer
A new model of ovarian cancer tumor progression implicates aberrant FANCF promoter methylation that is associated with
gene silencing and disruption of the Fanconi-anemia-BRCA pathway. Disruption of the pathway occurs de novo in ovarian
cancers and may contribute to selective sensitivity to platinum salts.
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abnormalities in proteins upstream of
FANCD2 in the FA-BRCA pathway. Only
FANCF was able to correct the defect in
FANCD2 monoubiquitination in the
transfected cells. The FANCF-corrected
TOV-21G cells became resistant to MMC
and CDDP with IC50 > 1 µm CDDP. No
FANCF gene mutations were found in
TOV-21G, but its promoter was densely
methylated. Two additional cell lines,
C13*, a CDDP-resistant derivative of
2008 with low levels of FANCF protein
and OAW42, a cell line derived from the
ascites of a woman previously exposed
to CDDP, were also methylated. When
C13* was treated with 5-aza-2’-deoxycy-
tidine, a demethylating agent, FANCF
mRNA expression and monoubiquina-
tion of FANCD2 were restored.The treat-
ed C13* cells then became less sensitive
to CDDP. The authors established a
more general role for FANCF promoter
methylation in ovarian cancer with the
observation that 4 of 19 (21%) primary
ovarian cancers, not previously exposed
to CDDP, also demonstrated FANCF
methylation. Thus, their study suggests
that disruption of the FANC-BRCA path-
way occurs de novo in ovarian cancers
and may contribute to selective sensitivi-
ty to platinum salts, which has significant
clinical implication.
Fanconi anemia patients are predis-
posed to many types of cancer, including
acute myeloid leukemia, squamous cell
carcinoma of the head and neck, gyne-
cological cancers, and esophageal can-
cer. About 10% of women diagnosed
with breast or ovarian cancer each year
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Figure 1. The Fanconi anemia/BRCA pathway and inactivation of BRCA1 in breast/ovarian cancer
A: FANCD2 protein functions at the intersection of two signaling pathways. In response to ionizing radiation-mediated double-strand breaks
(DSB), ATM phosphorylates the NBS1 protein. Phosphorylation of NBS1 is required for FANCD2 phosphorylation at serine 222 (S222), leading to acti-
vation of an S phase checkpoint. In response to DNA damage, the FA complex mediates the Ub of FANCD2 at lysine 561. Activated FANCD2 is
translocated to chromatin and DNA repair foci, which contain the BRCA1 protein and BRCA2/FANCD1 protein complex. BRCA2/FANCD1 binds
to RAD51 and to DNA, promoting a DNA repair response. The Ub-FANCD2 also colocalizes with NBS-MRE11-RAD50 complex in DNA damage
nuclear foci.
B: The mechanism of inactivation of BRCA1 in breast/ovarian cancer. Hypermethylation of the BRCA1 promoter was detected in sporadic breast
and ovarian cancer samples with proportions ranging from 11% to 31% and from 5% to 15%, respectively. This model shows that promoter methy-
lation can serve as a “first hit” in the BRCA1 and FANCF genes just as inherited mutation can serve as a “first hit” in the BRCA1 and BRCA2 genes.
In cases where the first copy is methylated, the second copy may be inactivated by LOH or methylation.
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are estimated to carry highly penetrant,
germline mutations in the BRCA1 or
BRCA2 gene (Antoniou et al., 2003).
Somatic mutations of BRCA1 or BRCA2
genes are rare, yet epigenetic changes
in the form of promoter methylation
resulting in transcriptional silencing of
the BRCA1 gene have been demonstrat-
ed in about 5%–15% of nonfamilial ovar-
ian cancer cases and 11%–31% of
nonfamilial breast cancers (Catteau and
Morris, 2002). Interestingly, BRCA2 is
generally hypomethylated and overex-
pressed in breast and ovarian cancers
(Collins et al., 1997). Though the num-
bers are small, this study suggests that
8% of established ovarian cancer cell
lines and about 20% of primary ovarian
cancers have hypermethylation at the
FANCF gene promoter. It is not clear
whether methylation was bi-allelic or
associated with gross chromosomal
deletion or loss of heterozygosity (LOH)
in the primary tumors. FANCF gene is
located on the short arm of chromosome
11, band p15 (11p15), a region contain-
ing a number of imprinted genes associ-
ated with cancer, which is also frequently
lost in ovarian cancer and other tumor
types (Lu et al., 1997). In a preliminary
study of 75 primary breast tumors, we
have observed 13 tumors with FANCF
promoter methylation. Further explo-
ration of the epigenetic silencing of
FANCF gene will likely provide insight
into the etiology of nonfamilial cancers
as has been demonstrated for the
BRCA1 gene.
DNA microarray analyses indicate
that breast cancers arising in the setting
of germline BRCA1 mutations have
unique gene expression profiles, which
are identical to sporadic tumors with
methylated BRCA1 and distinct from
other types of breast cancer (van’t Veer
et al., 2002). The observed similarities
between BRCA1-mutated and some
BRCA1-methylated sporadic tumors
support a tumor progression model in
which early loss of BRCA1 causes
defects in chromosome structure, cell
division, and viability, so that a BRCA1-
deficient cell must acquire additional
alterations that overcome these prob-
lems and presumably force tumor evolu-
tion down a limited set of pathways
(Venkitaraman, 2002). While it is not
clear that methylation of FANCF will have
similar effects as BRCA1, a model of car-
cinogenesis involving the FA-BRCA
pathway can be proposed in which pro-
moter methylation can serve as a “first
hit” in the BRCA1 or FANCF genes just
as inherited mutation can serve as a
“first hit” in the BRCA1 and BRCA2
genes (Figure 1B). In cases where the
first copy is methylated, the second copy
may be inactivated by LOH or methyla-
tion.
Taniguchi et al. (2003) also provide
further evidence that, as is the case with
deleterious point mutations and gross
chromosomal deletions, aberrant pro-
moter methylation is associated with a
loss of gene function that can provide a
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Figure 2. The heterogeneity of DNA methylaiton and gene expression
In cancer, the dynamics of genetically and epigenetically mediated loss of gene function are very different. The results of the progressive and
heterogeneous methylation are an increasing degree of transcriptional loss and a variable decrease in protein production in individual cells of
tumor.
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selective advantage to transformed cells.
However, in contrast to the clonal evolu-
tion associated with genetic mutations,
promoter CpG island hypermethylation is
a more gradual and progressive process
(Jones and Baylin, 2002). The process
can vary between individual DNA
strands and between cells, creating
methylation heterogeneity even in long
established cell culture. Because the
degree of transcriptional silencing is usu-
ally dependent on the density of methy-
lated CpG sites in the island, this
methylation heterogeneity can lead to
heterogeneous populations of cells with
varying levels of gene expression and
different properties (Figure 2). This phe-
nomenon could, in part, explain why
OAW42 cell line that has 54% of its CpG
sites methylated is partially CDDP sensi-
tive while 2008 cell line that is 95%
methylated is CDDP hypersensitive.
Likewise, while initial methylation of
FANCF followed by FANCF demethyla-
tion could be one explanation for the
observed CDDP resistance in C13* cell
line, methylation heterogeneity might
also explain the phenomenon. It is con-
ceivable that CDDP eradicated cells with
the highest degree of methylation, leav-
ing an outgrowth of a population of cells
that are nonmethylated.
This study raises important ques-
tions regarding the use of demethylating
agents in the treatment of ovarian can-
cer. We do not know nearly enough
about the different pathways that are
subject to epigenetic silencing, hence
clinical trials using these agents should
proceed cautiously. Nonetheless, we
now have sophisticated techniques to
detect de novo methylation, and these
tools should prove useful as we develop
novel strategies for the early detection,
prevention, and treatment of ovarian
cancer.
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